New reports from drugmaker Janssen (left) and PhRMA recommend taking 340B drug discounts away from hospitals and contract pharmacies and giving them to patients.

Pharma’s Plans to Rebuild Health Care Include Overhauling 340B

New reports from pharmacy giant Janssen and Pharmaceutical Research and Manufacturers of America (PhRMA) suggest that the pharma sector could be making the 340B program an even bigger target than it has been in recent years.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »